SP-8356, a novel inhibitor of CD147-cyclophilin a interactions, reduces plaque progression and stabilizes vulnerable plaques in apoE-deficient mice

Kisoo Pahk, Chanmin Joung, Hwa Young Song, Sungeun Kim, Won Ki Kim

Research output: Contribution to journalArticle

Abstract

Interactions between CD147 and cyclophilin A (CypA) promote plaque rupture that causes atherosclerosis-related cardiovascular events, such as myocardial infarction and stroke. Here, we investigated whether SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one), a novel drug, can exert therapeutic effects against plaque progression and instability through disruption of CD147-CypA interactions in apolipoprotein E-deficient (ApoE KO) mice. Immunocytochemistry and immunoprecipitation analyses were performed to assess the effects of SP-8356 on CD147-CypA interactions. Advanced plaques were induced in ApoE KO mice via partial ligation of the right carotid artery coupled with an atherogenic diet, and SP-8356 (50 mg/kg) orally administrated daily one day after carotid artery ligation for three weeks. The anti-atherosclerotic effect of SP-8356 was assessed using histological and molecular approaches. SP-8356 interfered with CD147-CypA interactions and attenuated matrix metalloproteinase-9 activation. Moreover, SP-8356 induced a decreased in atherosclerotic plaque size in ApoE KO mice and stabilized plaque vulnerability by reducing the necrotic lipid core, suppressing macrophage infiltration, and enhancing fibrous cap thickness through increasing the content of vascular smooth muscle cells. SP-8356 exerts remarkable anti-atherosclerotic effects by suppressing plaque development and improving plaque stability through inhibiting CD147-CypA interactions. Our novel findings support the potential utility of SP-8356 as a therapeutic agent for atherosclerotic plaque.

Original languageEnglish
Article number95
JournalInternational journal of molecular sciences
Volume21
Issue number1
DOIs
Publication statusPublished - 2020 Jan 1

Fingerprint

Cyclophilin A
Cyclophilins
Apolipoproteins E
progressions
inhibitors
mice
Macrophages
Nutrition
Infiltration
Lipids
Muscle
Atherosclerotic Plaques
arteries
Carotid Arteries
Chemical activation
Cells
interactions
Ligation
myocardial infarction
Atherogenic Diet

Keywords

  • Atherosclerosis
  • Cluster of differentiation 147 (CD147)
  • Matrix metalloproteinase
  • Matrix metalloproteinase-9 (MMP-9)
  • Plaque
  • Plaque vulnerability

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

SP-8356, a novel inhibitor of CD147-cyclophilin a interactions, reduces plaque progression and stabilizes vulnerable plaques in apoE-deficient mice. / Pahk, Kisoo; Joung, Chanmin; Song, Hwa Young; Kim, Sungeun; Kim, Won Ki.

In: International journal of molecular sciences, Vol. 21, No. 1, 95, 01.01.2020.

Research output: Contribution to journalArticle

@article{b6472e05dda74ae89d456a3b62c6309a,
title = "SP-8356, a novel inhibitor of CD147-cyclophilin a interactions, reduces plaque progression and stabilizes vulnerable plaques in apoE-deficient mice",
abstract = "Interactions between CD147 and cyclophilin A (CypA) promote plaque rupture that causes atherosclerosis-related cardiovascular events, such as myocardial infarction and stroke. Here, we investigated whether SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one), a novel drug, can exert therapeutic effects against plaque progression and instability through disruption of CD147-CypA interactions in apolipoprotein E-deficient (ApoE KO) mice. Immunocytochemistry and immunoprecipitation analyses were performed to assess the effects of SP-8356 on CD147-CypA interactions. Advanced plaques were induced in ApoE KO mice via partial ligation of the right carotid artery coupled with an atherogenic diet, and SP-8356 (50 mg/kg) orally administrated daily one day after carotid artery ligation for three weeks. The anti-atherosclerotic effect of SP-8356 was assessed using histological and molecular approaches. SP-8356 interfered with CD147-CypA interactions and attenuated matrix metalloproteinase-9 activation. Moreover, SP-8356 induced a decreased in atherosclerotic plaque size in ApoE KO mice and stabilized plaque vulnerability by reducing the necrotic lipid core, suppressing macrophage infiltration, and enhancing fibrous cap thickness through increasing the content of vascular smooth muscle cells. SP-8356 exerts remarkable anti-atherosclerotic effects by suppressing plaque development and improving plaque stability through inhibiting CD147-CypA interactions. Our novel findings support the potential utility of SP-8356 as a therapeutic agent for atherosclerotic plaque.",
keywords = "Atherosclerosis, Cluster of differentiation 147 (CD147), Matrix metalloproteinase, Matrix metalloproteinase-9 (MMP-9), Plaque, Plaque vulnerability",
author = "Kisoo Pahk and Chanmin Joung and Song, {Hwa Young} and Sungeun Kim and Kim, {Won Ki}",
year = "2020",
month = "1",
day = "1",
doi = "10.3390/ijms21010095",
language = "English",
volume = "21",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - SP-8356, a novel inhibitor of CD147-cyclophilin a interactions, reduces plaque progression and stabilizes vulnerable plaques in apoE-deficient mice

AU - Pahk, Kisoo

AU - Joung, Chanmin

AU - Song, Hwa Young

AU - Kim, Sungeun

AU - Kim, Won Ki

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Interactions between CD147 and cyclophilin A (CypA) promote plaque rupture that causes atherosclerosis-related cardiovascular events, such as myocardial infarction and stroke. Here, we investigated whether SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one), a novel drug, can exert therapeutic effects against plaque progression and instability through disruption of CD147-CypA interactions in apolipoprotein E-deficient (ApoE KO) mice. Immunocytochemistry and immunoprecipitation analyses were performed to assess the effects of SP-8356 on CD147-CypA interactions. Advanced plaques were induced in ApoE KO mice via partial ligation of the right carotid artery coupled with an atherogenic diet, and SP-8356 (50 mg/kg) orally administrated daily one day after carotid artery ligation for three weeks. The anti-atherosclerotic effect of SP-8356 was assessed using histological and molecular approaches. SP-8356 interfered with CD147-CypA interactions and attenuated matrix metalloproteinase-9 activation. Moreover, SP-8356 induced a decreased in atherosclerotic plaque size in ApoE KO mice and stabilized plaque vulnerability by reducing the necrotic lipid core, suppressing macrophage infiltration, and enhancing fibrous cap thickness through increasing the content of vascular smooth muscle cells. SP-8356 exerts remarkable anti-atherosclerotic effects by suppressing plaque development and improving plaque stability through inhibiting CD147-CypA interactions. Our novel findings support the potential utility of SP-8356 as a therapeutic agent for atherosclerotic plaque.

AB - Interactions between CD147 and cyclophilin A (CypA) promote plaque rupture that causes atherosclerosis-related cardiovascular events, such as myocardial infarction and stroke. Here, we investigated whether SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one), a novel drug, can exert therapeutic effects against plaque progression and instability through disruption of CD147-CypA interactions in apolipoprotein E-deficient (ApoE KO) mice. Immunocytochemistry and immunoprecipitation analyses were performed to assess the effects of SP-8356 on CD147-CypA interactions. Advanced plaques were induced in ApoE KO mice via partial ligation of the right carotid artery coupled with an atherogenic diet, and SP-8356 (50 mg/kg) orally administrated daily one day after carotid artery ligation for three weeks. The anti-atherosclerotic effect of SP-8356 was assessed using histological and molecular approaches. SP-8356 interfered with CD147-CypA interactions and attenuated matrix metalloproteinase-9 activation. Moreover, SP-8356 induced a decreased in atherosclerotic plaque size in ApoE KO mice and stabilized plaque vulnerability by reducing the necrotic lipid core, suppressing macrophage infiltration, and enhancing fibrous cap thickness through increasing the content of vascular smooth muscle cells. SP-8356 exerts remarkable anti-atherosclerotic effects by suppressing plaque development and improving plaque stability through inhibiting CD147-CypA interactions. Our novel findings support the potential utility of SP-8356 as a therapeutic agent for atherosclerotic plaque.

KW - Atherosclerosis

KW - Cluster of differentiation 147 (CD147)

KW - Matrix metalloproteinase

KW - Matrix metalloproteinase-9 (MMP-9)

KW - Plaque

KW - Plaque vulnerability

UR - http://www.scopus.com/inward/record.url?scp=85076916352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076916352&partnerID=8YFLogxK

U2 - 10.3390/ijms21010095

DO - 10.3390/ijms21010095

M3 - Article

C2 - 31877775

AN - SCOPUS:85076916352

VL - 21

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 1

M1 - 95

ER -